Company News
Mentara Bio Inc. Initiates Phase 2 Study of MN-301, an Innovative Antiepileptic Compound
May 13, 2024
Mentara Bio Inc. (“Mentara Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing neurocircuit-selective medicines for neurological disorders, announced today its plans to commence a Phase 2 clinical trial of MN-301 for the treatment of epilepsy. MN-301 is a novel, highly selective compound targeting specific receptors involved in epilepsy pathways, developed in collaboration with leading academic institutions.
Mentara Bio Inc. Initiates Phase 2 Study of MN-301, an Innovative Antiepileptic Compound
May 13, 2024
Mentara Bio Inc. (“Mentara Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing neurocircuit-selective medicines for neurological disorders, announced today its plans to commence a Phase 2 clinical trial of MN-301 for the treatment of epilepsy. MN-301 is a novel, highly selective compound targeting specific receptors involved in epilepsy pathways, developed in collaboration with leading academic institutions.
Mentara Bio Inc. Announces Closing of Series A Financing
March 06, 2023
Mentara Bio Inc. (“Mentara Bio” or the “Company”), a biopharmaceutical company committed to developing innovative treatments for neurological conditions, today announced the successful closing of its $4.1 million Series A financing round. This funding will enable the Company to complete the necessary IND-enabling studies for its lead product candidate, MN-045, in preparation for Phase 1 clinical trials planned for the latter half of 2023.
Mentara Bio Inc. Launches to Develop Advanced Treatments for Epilepsy and Dravet Syndrome
February 15, 2022
Mentara Bio Inc. (“Mentara Bio” or “the Company”), a pioneering biopharmaceutical firm, is proud to announce its official launch with a dedicated mission to develop innovative treatments for epilepsy and related neurological disorders, including Dravet syndrome. The Company’s leading candidate, MN-045, has demonstrated exceptional promise in preclinical studies and is on the path to an Investigational New Drug (IND) application, supported by $2M in Small Business Innovation Research (SBIR) awards.
Mentara Bio Inc. Launches to Develop Advanced Treatments for Epilepsy and Dravet Syndrome
April 15, 2021
Mentara Bio Inc. (“Mentara Bio” or “the Company”), a pioneering biopharmaceutical firm, is proud to announce its official launch with a dedicated mission to develop innovative treatments for epilepsy and related neurological disorders, including Dravet syndrome. The Company’s leading candidate, MN-045, has demonstrated exceptional promise in preclinical studies and is on the path to an Investigational New Drug (IND) application, supported by $2M in Small Business Innovation Research (SBIR) awards.